TherapeuticsMD (NASDAQ:TXMD) Director Tommy Thompson Buys 8,400 Shares

TherapeuticsMD, Inc. (NASDAQ:TXMD) Director Tommy Thompson bought 8,400 shares of the business’s stock in a transaction that occurred on Tuesday, December 23rd. The stock was purchased at an average cost of $1.67 per share, for a total transaction of $14,028.00. Following the completion of the transaction, the director owned 23,179 shares in the company, valued at $38,708.93. This trade represents a 56.84% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

TherapeuticsMD Price Performance

TXMD traded down $0.06 on Monday, reaching $1.68. 71,746 shares of the stock were exchanged, compared to its average volume of 215,085. The company’s 50-day moving average price is $1.54 and its 200 day moving average price is $1.26. The firm has a market capitalization of $19.44 million, a PE ratio of -168.00 and a beta of 0.41. TherapeuticsMD, Inc. has a fifty-two week low of $0.70 and a fifty-two week high of $2.44.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Wednesday, November 12th. The company reported $0.01 earnings per share (EPS) for the quarter. TherapeuticsMD had a return on equity of 0.27% and a net margin of 10.80%.The firm had revenue of $0.78 million during the quarter.

Institutional Investors Weigh In On TherapeuticsMD

An institutional investor recently raised its position in TherapeuticsMD stock. Citadel Advisors LLC grew its position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 125.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,273 shares of the company’s stock after purchasing an additional 19,073 shares during the quarter. Citadel Advisors LLC owned approximately 0.30% of TherapeuticsMD worth $36,000 as of its most recent SEC filing. 30.74% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of TherapeuticsMD in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, TherapeuticsMD presently has an average rating of “Sell”.

About TherapeuticsMD

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.